Kewaunee Scientific Corp Reports 18% Revenue Surge to $240.5M in FY 2025, Driven by Domestic Sales Growth

Reuters
07/02
Kewaunee Scientific Corp Reports 18% Revenue Surge to $240.5M in FY 2025, Driven by Domestic Sales Growth

Kewaunee Scientific Corporation has reported its financial results for the fiscal year ending April 30, 2025. The company, known for its laboratory, healthcare, and technical furniture solutions, achieved sales of $240.5 million, marking a notable increase from the previous fiscal year's sales of $203.8 million. Breaking down the sales, the Domestic Segment saw an impressive rise to $179.4 million, a 30.7% increase from the $137.2 million reported in fiscal year 2024. This growth was significantly influenced by the acquisition of Nu Aire on November 1, 2024. On the other hand, the International Segment experienced a decline in sales, reporting $61.1 million, which is an 8.2% decrease compared to the $66.5 million in the prior fiscal year. The decrease in international sales was attributed to customer site delays in India. Looking ahead, Kewaunee Scientific Corporation acknowledges the challenges in predicting future product demand due to its subcontractor role and dependence on laboratory and healthcare construction projects. Additionally, fluctuations in raw material costs, such as steel, wood, and epoxy resin, are expected to impact earnings. The acquisition of Nu Aire is seen as a strategic move to enhance growth, combining strengths in laboratory and biosafety solutions and aligning with a shared vision for laboratory innovation.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kewaunee Scientific Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0000055529-25-000026), on July 02, 2025, and is solely responsible for the information contained therein.

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10